Literature DB >> 9057653

Higher frequency of glutathione S-transferase deletions in black children with acute lymphoblastic leukemia.

C L Chen1, Q Liu, C H Pui, G K Rivera, J T Sandlund, R Ribeiro, W E Evans, M V Relling.   

Abstract

The genetic polymorphisms in human glutathione S-transferases (GST) M1 and T1 have been associated with race, disease risk, and outcome of some adult cancers. Also, there are racial differences in the incidence and characteristics of childhood acute lymphoblastic leukemia (ALL). Our objectives were to compare the frequency of the null genotype for GSTM1, GSTT1, or both in children with ALL to that in healthy controls, and to determine whether GST genotype was associated with treatment outcome and prognostic factors. We studied GSTM1 and GSTT1 genotypes in somatic cell DNA from black children and white children with ALL and in 416 healthy controls, using a polymerase chain reaction technique. Ninety of 163 (55.2%) white ALL patients and 14 of 34 (41.2%) black patients were GSTM1 null, frequencies not significantly different (P = .19) than healthy controls (53.5% in whites and 27.6% in blacks), although there was a trend toward more null genotypes in black ALL patients. Twenty-three of 163 (14.1%) white ALL patients and 12 of 34 (35.3%) black ALL patients were GSTT1 null, not different (P = .34) than the frequencies in healthy controls (15.0% in whites and 24.1% in blacks). However, the frequency of the "double-null" genotype, lacking both GSTM1 and GSTT1, was higher in black patients with ALL (8 of 34 or 23.5%) than in black controls (3.9%) (P = .0005), but this was not the case in white patients with ALL (10 of 163 or 6.1%) compared to white controls (8.0%) (P = .68). In stratified analyses, the GST double-null genotype was not associated with other characteristics that might differ between whites and blacks with ALL, such as age, T-lineage immunophenotype, presenting white blood cell count, DNA index, or insurance status. The null genotype for GSTM1, GSTT1, or both was not found to be a prognostic factor for disease-free survival or probability of hematologic remission; central nervous system relapse tended to be less common in those with the GSTM1 null genotype (P = .054). The double-null genotype for GSTM1 and GSTT1 is more common among blacks but not whites with childhood ALL. These data suggest that GST genotype, coupled with unidentified additional risk factors, may play a role in risk of childhood ALL in American blacks.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9057653

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  32 in total

1.  Frequency of glutathione-S-transferase gene deletions in children with neoplasms.

Authors:  Elzbieta Zielinska; Malgorzata Zubowska; Karolina Przybylowska; Jerzy Bodalski
Journal:  Eur J Pediatr       Date:  2002-01       Impact factor: 3.183

2.  Immune function in healthy inner-city children.

Authors:  J A Bartlett; A R Goldklang; S J Schleifer; S E Keller
Journal:  Clin Diagn Lab Immunol       Date:  2001-07

Review 3.  Candidate gene association studies and risk of childhood acute lymphoblastic leukemia: a systematic review and meta-analysis.

Authors:  Jayaram Vijayakrishnan; Richard S Houlston
Journal:  Haematologica       Date:  2010-05-29       Impact factor: 9.941

4.  Association of glutathione S-transferase T1 and M1 genotypes with chronic liver diseases among Filipinos.

Authors:  Michael O Baclig; May R Alvarez; Xerxes Morgan R Lozada; Cynthia A Mapua; Jingky P Lozano-Kühne; Mark Pierre S Dimamay; Filipinas F Natividad; Juliet Gopez-Cervantes; Ronald R Matias
Journal:  Int J Mol Epidemiol Genet       Date:  2012-05-15

5.  A comparison of glutathione S-transferase mutant frequencies in healthy Han and Uygur Chinese.

Authors:  Shi-Long Zhong; Shufeng Zhou; Min Huang
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2005 Jul-Sep       Impact factor: 2.441

6.  Glutathione-S-transferase-P1 I105V polymorphism and response to antenatal betamethasone in the prevention of respiratory distress syndrome.

Authors:  Chiara Oretti; Sara Marino; Fabio Mosca; Maria Rosa Colnaghi; Sara De Iudicibus; Ilenia Drigo; Gabriele Stocco; Fiora Bartoli; Giuliana Decorti; Sergio Demarini
Journal:  Eur J Clin Pharmacol       Date:  2009-01-29       Impact factor: 2.953

7.  Pharmacogenetics of outcome in children with acute lymphoblastic leukemia.

Authors:  Jose Claudio C Rocha; Cheng Cheng; Wei Liu; Shinji Kishi; Soma Das; Edwin H Cook; John T Sandlund; Jeffrey Rubnitz; Raul Ribeiro; Dario Campana; Ching-Hon Pui; William E Evans; Mary V Relling
Journal:  Blood       Date:  2005-02-15       Impact factor: 22.113

8.  A meta-analysis of genotypes and haplotypes of methylenetetrahydrofolate reductase gene polymorphisms in acute lymphoblastic leukemia.

Authors:  Elias Zintzaras; Theocharis Koufakis; Panayiotis D Ziakas; Paraskevi Rodopoulou; Stavroula Giannouli; Michael Voulgarelis
Journal:  Eur J Epidemiol       Date:  2006-08-09       Impact factor: 8.082

Review 9.  Genetic polymorphisms of drug-metabolising enzymes and drug transporters in the chemotherapeutic treatment of cancer.

Authors:  Tessa M Bosch; Irma Meijerman; Jos H Beijnen; Jan H M Schellens
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

10.  GSTT1 genetic polymorphism and susceptibility to childhood acute lymphoblastic leukemia: a meta-analysis.

Authors:  Ling-Yun Xu; Lan-Fang Cao
Journal:  Tumour Biol       Date:  2013-11-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.